About Global X Japan Bio & Med Tech ETF

2639 invests in stocks. The fund's major sectors are Health Technology, with 80.82% stocks, and Distribution Services, with 9.35% of the basket. The assets are mostly located in the Asia region.

2639 top holdings are Shionogi & Co., Ltd. and Shimadzu Corporation, occupying 9.61% and 7.91% of the portfolio correspondingly.

2639 last dividends amounted to 4.00 JPY. Six months before that, the issuer paid 18.00 JPY in dividends, which shows a 350.00% decrease.

2639 assets under management is ‪979.99 M‬ JPY. It's risen 3.04% over the last month.

2639 fund flows account for ‪16.85 M‬ JPY (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.

2639 shares are issued by Mirae Asset Global Investments Co., Ltd. under the brand Global X. The ETF was launched on Jun 21, 2021, and its management style is Passive.

2639 expense ratio is 0.59% meaning you'd have to pay 0.59% of your investment to help manage the fund.

2639 follows the FactSet Japan Bio & Med Technologies Index - JPY - Benchmark TR Net. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.

2639 invests in stocks.

2639 price has risen by 0.46% over the last month, and its yearly performance shows a 7.98% increase. See more dynamics on 2639 price chart.
NAV returns, another gauge of an ETF dynamics, have risen by 0.63% over the last month, showed a 6.84% increase in three-month performance and has increased by 9.51% in a year.